QV Bioelectronics is developing GRACE, an implantable electric field therapy (EFT) device intended to disrupt cancer cell growth in the brain by applying electrical fields at specific frequencies. The company is undertaking pre‑clinical studies and expects the device to operate without harming healthy brain cells. QV plans to tackle glioblastoma first and to deliver the implant to patients during mainstream surgical treatment to maximise safety and cost‑effectiveness. The funding will be used to expand pre‑clinical research and to finalise an initial product design. Proceeds will also support QV's commercial strategy and regulatory pipeline as it prepares the EFT for clinical‑grade testing. The founding team includes specialty neurosurgery registrar Dr Richard Fu and CEO Dr Christopher Bullock. The company is based in Cheshire, UK and recently raised new capital to advance development. QV Bioelectronics, founded in 2018 by Christopher Bullock and Richard Fu, is developing the GRACE implant — a first-of-its-kind electric field therapy device aimed at treating glioblastoma. The technology uses advanced materials and is designed to extend patient life expectancy without negatively affecting quality of life. The company has worked with leading UK neurosurgeons on prototype design and remains at an early development stage; it expects several years before the device enters clinical trials. QV recently closed an oversubscribed £735K seed round to advance GRACE's development and grow its team. Prior to this round it had raised over £350K in a mix of equity and grants, including a pre-seed from SOSV and grants from Innovate UK and the National Institute for Health Research. The company plans to use the new funds to push the technology toward clinical readiness while leveraging investor expertise and networks.

Total raised

$3M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2023